Immune-related adverse events

This is a summary of the peer-reviewed article: Management of immune-related adverse events in oncology settings by Laura Collantes Espinosa and Catia Da Costa Mendes.  The article describes how immune checkpoint inhibitors (ICIs) have transformed cancer treatment by enhancing immune responses against various cancers, such as melanoma, lung and renal cancers. Despite their efficacy, ICIs frequently cause immune-related adverse events (irAEs). Prompt recognition and management of irAEs is critical for optimising patient outcomes and ensuring patient safety